Drug Profile

SIG 001

Alternative Names: B-domain deleted human factor VIII (BDD-hFVIII) producing spheres - Sigilon Therapeutics; SIG-001

Latest Information Update: 18 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sigilon Therapeutics
Class Cell therapies; Gene therapies
Mechanism of Action Cell replacements; Factor VII replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Haemophilia A

Most Recent Events

14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
05 May 2023 The US FDA withdraws Orphan Drug status for Haemophilia A in the US, prior to May 2023
10 Nov 2022 Sigilon Therapeutics withdrew its CTA for SIG 001 in Haemophilia A

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com